Comparison of Diagnostic Value between 99mTechnetium-Methylene Diphosphate Bone Scan and 99mTechnetium-Prostate-specific Membrane Antigen Scan in Patients with Prostate Cancer with Osseous Metastases.

Background: Prostate cancer (PCa) ranks as the second most prevalent cancer among men globally. The utilization of efficient and cost-effective diagnostic and therapeutic approaches holds paramount importance in the diagnosis and treatment of these patients, significantly impacting treatment outcomes. This study focuses on the investigation and comparison of two commonly employed scans within the treatment process for these patients.

Methods: In this prospective study, which spanned over 2 years, 40 patients diagnosed with PCa underwent examination using two scans: ^99m Technetium-Prostate-specific Membrane Antigen (^99mTC-PSMA) Scan and between Technetium-Methylene Diphosphate (^99mTC-MDP) Bone Scan. The findings of these scans were then compared with each other, as well as with the results obtained from magnetic resonance imaging and the prostate-specific antigen level. The analysis of the results was conducted utilizing SPSS 22 software, and descriptive statistical methods were employed to present the findings.

Results: In this prospective study, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the ^99mTC-MDP Bone Scan were found to be 88.2%, 83.3%, 96.7%, 55.5%, and 87.5%, respectively. Similarly, for the ^99mTC-PSMA Scan, the corresponding values were 94.1%, 83.3%, 96.4%, 83.3%, and 92.5%, respectively.

Conclusions: Based on the findings of this study, it can be concluded that the diagnostic accuracy of the ^99mTC-PSMA Scan is marginally higher compared to the ^99mTC-MDP Bone Scan. Therefore, for patients who are limited to only one scan, the ^99mTC-PSMA Scan appears to be the preferable choice.